• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Mycobacterium Tuberculosis Infections - Pipeline Review, H1 2013 Product Image

Mycobacterium Tuberculosis Infections - Pipeline Review, H1 2013

  • ID: 2517864
  • March 2013
  • 253 pages
  • Global Markets Direct

Mycobacterium Tuberculosis Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Mycobacterium Tuberculosis Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mycobacterium Tuberculosis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mycobacterium Tuberculosis Infections. Mycobacterium Tuberculosis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mycobacterium Tuberculosis READ MORE >

2
List of Tables 7
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Mycobacterium Tuberculosis Infections Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Mycobacterium Tuberculosis Infections 12
Mycobacterium Tuberculosis Infections Therapeutics under Development by Companies 14
Mycobacterium Tuberculosis Infections Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Mycobacterium Tuberculosis Infections Therapeutics – Products under Development by Companies 27
Mycobacterium Tuberculosis Infections Therapeutics – Products under Investigation by Universities/Institutes 33
Companies Involved in Mycobacterium Tuberculosis Infections Therapeutics Development 36
Johnson & Johnson 36
Sequella, Inc. 37
AstraZeneca PLC 38
Eli Lilly and Company 39
GlaxoSmithKline plc 40
FASgen, Inc. 41
Emergent BioSolutions Inc. 42
Achillion Pharmaceuticals, Inc. 43
Pfizer Inc. 44
Vertex Pharmaceuticals Incorporated 45
AVI BioPharma Inc. 46
Crucell N.V. 47
Affinium Pharmaceuticals, Inc. 48
Hollis-Eden Pharmaceuticals, Inc. 49
Intercell AG 50
Lupin Limited 51
Oragenics, Inc. 52
Transgene SA 53
Summit Corporation plc 54
PolyMedix, Inc. 55
Immune Network Research Ltd. 56
Aeras Global Tb Vaccine Foundation 57
Snowdon Inc. 58
ImmunoBiology Limited 59
Recipharm AB 60
MicuRx Pharmaceuticals, Inc. 61
Mondobiotech Holding AG 62
EpiVax, Inc. 63
Archivel Farma S.L. 64
Chimerix, Inc. 65
Pharminox Limited 66
ImmunoVaccine Technologies Inc. 67
Canopus BioPharma Incorporated 68
Avir Green Hills Biotechnology AG 69
TVAX Biomedical, LLC 70
Medisyn Technologies, Inc. 71
Ascenion GmbH 72
Vakzine Projekt Management GmbH 73
B&C Biopharm 74
NeED Pharma s.r.l. 75
Vichem Chemie Research Ltd. 76
ISA Pharmaceuticals B.V. 77
Lipotek Pty Ltd 78
Mycobacterium Tuberculosis Infections – Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
delamanid - Drug Profile 85
delamanid - Drug Profile 87
SND-159 - Drug Profile 89
PMX-10072 - Drug Profile 90
bedaquiline - Drug Profile 91
SQ-109 - Drug Profile 93
MVA-85A - Drug Profile 95
MU-1140 - Drug Profile 98
Tuberculosis Vaccine - Drug Profile 100
rifalazil - Drug Profile 101
SQ-609 - Drug Profile 103
NasL3/HtkBCG - Drug Profile 104
MTBVAC01 - Drug Profile 105
FAS-20013 - Drug Profile 106
sutezolid - Drug Profile 107
VPM-1002 - Drug Profile 108
HG-85A/B - Drug Profile 109
HG856-A - Drug Profile 110
VecFlu - Drug Profile 111
PS-Conjugate Vaccine - Drug Profile 112
GSK-692342 - Drug Profile 113
r30 - Drug Profile 114
TB proteasome inhibitor program - Drug Profile 115
AERAS-Capsid - Drug Profile 116
HBHA - Drug Profile 117
rBCG(mbtB)30 - Drug Profile 118
sudoterb - Drug Profile 119
Ad5Ag85A - Drug Profile 120
Drug For Tuberculosis - Drug Profile 121
Crucell Ad-35 - Drug Profile 122
RUTI Vaccine - Drug Profile 124
perforin - Drug Profile 125
Ag-85B-ESAT-6 - Drug Profile 126
AZD-5847 - Drug Profile 127
Vaccine For Tuberculosis - Drug Profile 129
RUTI + [isoniazid] - Drug Profile 130
PA-824 + [moxifloxacin hydrochloride] + [pyrazinamide] - Drug Profile 131
HE-2000 - Drug Profile 133
V-5 Immunitor - Drug Profile 135
PA-824 + [pyrazinamide] - Drug Profile 137
bedaquiline + [pyrazinamide] - Drug Profile 138
NasL3/AM85B - Drug Profile 139
Mycobacterial Liposomes And Proteosomal Vaccine - Drug Profile 140
paBCG Vaccine - Drug Profile 141
AERAS-422 - Drug Profile 142
rifalazil + [isoniazid] - Drug Profile 143
Drug For Tuberculosis - Drug Profile 144
FP6 TBVAC - Drug Profile 145
ORT-VAC DNA Vaccine - Drug Profile 146
IMX-TB2 - Drug Profile 147
DasKloster-024901 - Drug Profile 148
Anti-Bacterial Program - Drug Profile 149
PMX-10070 - Drug Profile 150
PMX-30053 - Drug Profile 151
TB-SLP - Drug Profile 152
Drug For Tuberculosis - Drug Profile 153
Bacterial PPMO - Drug Profile 154
MTbuVax - Drug Profile 155
Fabl Inhibitor Program - Drug Profile 156
SSI H56-IC31 - Drug Profile 157
MicroRNA-Like Molecules - Drug Profile 158
PMX-464 - Drug Profile 159
TVI-Tuberculosis-1 - Drug Profile 161
PM-181108 - Drug Profile 162
Tuberculosis Program - Drug Profile 163
IMX-461 - Drug Profile 165
V-7 Vaccine - Drug Profile 166
Mtb Vaccine - Drug Profile 168
HG85A - Drug Profile 169
TB Vaccine - Drug Profile 170
LIP1 Ac2SGL Sulfoglycolipid - Drug Profile 171
Latency Fusion Proteins Based Vaccine - Drug Profile 172
Recombinant LCMV - Drug Profile 173
pUMVC6/7 DNA - Drug Profile 174
IKEPLUS - Drug Profile 175
DNAacr - Drug Profile 176
LIP2 SL37 (synthetic) Sulfoglycolipid - Drug Profile 177
pascolizumab - Drug Profile 178
Anti-Tubercular Program - Drug Profile 179
H56 Vaccine - Drug Profile 180
TBA-354 - Drug Profile 182
MU-1140-S - Drug Profile 183
TB Therapeutic Vaccine - Drug Profile 185
BV-6602 - Drug Profile 186
Drug For Tuberculosis - Drug Profile 187
3-(4-chlorophenyl)-4-Substituted Pyrazole Compounds - Drug Profile 188
Anti-Tuberculosis Program - Drug Profile 189
mepenzolate bromide - Drug Profile 190
TB-A Series Program - Drug Profile 191
CPZEN-45 - Drug Profile 192
Tuberculosis Vaccine - Drug Profile 193
ND-801 - Drug Profile 194
ND-701 - Drug Profile 195
ND-201 - Drug Profile 196
ND-601 - Drug Profile 197
InhA inhibitors - Drug Profile 198
Drug for Tuberculosis - Drug Profile 199
BT Compound Systemic - Drug Profile 200
BT Compound Inhalation - Drug Profile 201
Enoyl Reductase Inhibitors - Drug Profile 202
ebselen - Drug Profile 203
Thiolactomycin Analogues - Drug Profile 204
Aminopyrazinamides - Drug Profile 205
Methionine Sulfoximine - Drug Profile 206
Recombinant BCG30 Vaccine - Drug Profile 207
Live Recombinant Booster Vaccine - Drug Profile 208
Tuberculosis Vaccine - Drug Profile 210
Tetramic Acid Analogs - Drug Profile 211
BV-6481 - Drug Profile 212
NM-031 - Drug Profile 213
MDR And XDR Tuberculosis Program - Drug Profile 214
Thuggacines - Drug Profile 215
ADX40-TB - Drug Profile 216
Drug For Infectious Diseases - Drug Profile 217
Tuberculosis Vaccine - Drug Profile 218
Mycobacterium Tuberculosis Infections Therapeutics – Drug Profile Updates 219
Mycobacterium Tuberculosis Infections Therapeutics – Discontinued Products 231
Mycobacterium Tuberculosis Infections Therapeutics - Dormant Products 232
Mycobacterium Tuberculosis Infections – Product Development Milestones 234
Featured News & Press Releases 234
Appendix 244
Methodology 244
Coverage 244
Secondary Research 244
Primary Research 244
Expert Panel Validation 244
Contact Us 245
Disclaimer 245

List of Tables
Number of Products Under Development for Mycobacterium Tuberculosis Infections, H1 2013 20
Products under Development for Mycobacterium Tuberculosis Infections – Comparative Analysis, H1 2013 21
Number of Products under Development by Companies, H1 2013 23
Number of Products under Development by Companies, H1 2013 (Contd..1) 24
Number of Products under Development by Companies, H1 2013 (Contd..2) 25
Number of Products under Development by Companies, H1 2013 (Contd..3) 26
Number of Products under Development by Companies, H1 2013 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2013 29
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 30
Comparative Analysis by Late Stage Development, H1 2013 31
Comparative Analysis by Mid Clinical Stage Development, H1 2013 32
Comparative Analysis by Early Clinical Stage Development, H1 2013 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 34
Products under Development by Companies, H1 2013 35
Products under Development by Companies, H1 2013 (Contd..1) 36
Products under Development by Companies, H1 2013 (Contd..2) 37
Products under Development by Companies, H1 2013 (Contd..3) 38
Products under Development by Companies, H1 2013 (Contd..4) 39
Products under Development by Companies, H1 2013 (Contd..5) 40
Products under Investigation by Universities/Institutes, H1 2013 41
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 42
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 43
Johnson & Johnson, H1 2013 44
Sequella, Inc., H1 2013 45
AstraZeneca PLC, H1 2013 46
Eli Lilly and Company, H1 2013 47
GlaxoSmithKline plc, H1 2013 48
FASgen, Inc., H1 2013 49
Emergent BioSolutions Inc., H1 2013 50
Achillion Pharmaceuticals, Inc., H1 2013 51
Pfizer Inc., H1 2013 52
Vertex Pharmaceuticals Incorporated, H1 2013 53
AVI BioPharma Inc., H1 2013 54
Crucell N.V., H1 2013 55
Affinium Pharmaceuticals, Inc., H1 2013 56
Hollis-Eden Pharmaceuticals, Inc., H1 2013 57
Intercell AG, H1 2013 58
Lupin Limited, H1 2013 59
Oragenics, Inc., H1 2013 60
Transgene SA, H1 2013 61
Summit Corporation plc, H1 2013 62
PolyMedix, Inc., H1 2013 63
Immune Network Research Ltd., H1 2013 64
Aeras Global Tb Vaccine Foundation, H1 2013 65
Snowdon Inc., H1 2013 66
ImmunoBiology Limited, H1 2013 67
Recipharm AB, H1 2013 68
MicuRx Pharmaceuticals, Inc., H1 2013 69
Mondobiotech Holding AG, H1 2013 70
EpiVax, Inc., H1 2013 71
Archivel Farma S.L., H1 2013 72
Chimerix, Inc., H1 2013 73
Pharminox Limited, H1 2013 74
ImmunoVaccine Technologies Inc., H1 2013 75
Canopus BioPharma Incorporated, H1 2013 76
Avir Green Hills Biotechnology AG, H1 2013 77
TVAX Biomedical, LLC, H1 2013 78
Medisyn Technologies, Inc., H1 2013 79
Ascenion GmbH, H1 2013 80
Vakzine Projekt Management GmbH, H1 2013 81
B&C Biopharm, H1 2013 82
NeED Pharma s.r.l., H1 2013 83
Vichem Chemie Research Ltd., H1 2013 84
ISA Pharmaceuticals B.V., H1 2013 85
Lipotek Pty Ltd, H1 2013 86
Assessment by Monotherapy Products, H1 2013 87
Assessment by Combination Products, H1 2013 88
Assessment by Stage and Route of Administration, H1 2013 90
Assessment by Stage and Molecule Type, H1 2013 92
Mycobacterium Tuberculosis Infections Therapeutics – Drug Profile Updates 227
Mycobacterium Tuberculosis Infections Therapeutics – Discontinued Products 239
Mycobacterium Tuberculosis Infections Therapeutics – Dormant Products 240
Mycobacterium Tuberculosis Infections Therapeutics – Dormant Products (Contd..1) 241

List of Figures
Number of Products under Development for Mycobacterium Tuberculosis Infections, H1 2013 20
Products under Development for Mycobacterium Tuberculosis Infections – Comparative Analysis, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Investigation by Universities/Institutes, H1 2013 28
Late Stage Products, H1 2013 31
Mid Clinical Stage Products, H1 2013 32
Early Clinical Stage Products, H1 2013 33
Discovery and Pre-Clinical Stage Products, H1 2013 34
Assessment by Monotherapy Products, H1 2013 87
Assessment by Combination Products, H1 2013 88
Assessment by Route of Administration, H1 2013 89
Assessment by Stage and Route of Administration, H1 2013 90
Assessment by Molecule Type, H1 2013 91
Assessment by Stage and Molecule Type, H1 2013 92

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos